(Reuters) – U.S. drug regulators are
changing the label for Merck & Co Inc’s recently approved Victrelis
treatment for hepatitis C to show it should not be taken with some
widely used HIV medicines.
“Co-administration (of the two
drugs) … is not recommended at this time because of the possibility of
reducing the effectiveness of the medicines, permitting the amount of
HCV (hepatitis C virus) or HIV … in the blood to increase,” the U.S.
Food and Drug Administration said on Thursday.